Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. TMU Publications / 北醫出版品
  3. .博碩士學位論文
  4. 108學年度
  5. 探討合併抑制第一型纖維母細胞生長因子受體及聚腺苷二磷酸核糖聚合酶治療胰管腺癌之轉譯研究
 
  • Details
Options

探討合併抑制第一型纖維母細胞生長因子受體及聚腺苷二磷酸核糖聚合酶治療胰管腺癌之轉譯研究

Other Title
Identification of Synthetic Lethality of FGFR1 Inhibitor in Combination with PARP1 Blockade in Pancreatic DuctalAdenocarcinoma
Type
thesis
Date Issued
2020-07-08
Author(s)
賴學緯
Advisor
趙祖怡
Subjects
系所名稱:臨床醫學研究所
Description
學位別:博士
語文別:英文
指導教授:趙祖怡
口試委員:葉大森 Ta-Sen Yeh;蕭宏昇 Hong-Shen Hsiao;黃奇英 Chi-Ying Huang;何景良 Ching-Liang Ho
電子論文連結:https://handle.ncl.edu.tw/11296/9r39uz
URI
https://203.71.86.71/handle/123456789/61112

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback